135 related articles for article (PubMed ID: 16936701)
1. EGFR is phosphorylated at Ty845 in hepatocellular carcinoma.
Kannangai R; Sahin F; Torbenson MS
Mod Pathol; 2006 Nov; 19(11):1456-61. PubMed ID: 16936701
[TBL] [Abstract][Full Text] [Related]
2. Diversity of epidermal growth factor receptor-mediated activation of downstream molecules in human lung carcinomas.
Suzuki S; Igarashi S; Hanawa M; Matsubara H; Ooi A; Dobashi Y
Mod Pathol; 2006 Jul; 19(7):986-98. PubMed ID: 16648865
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemistry panel segregates molecular types of hepatocellular carcinoma in Brazilian autopsy cases.
Felipe-Silva A; Wakamatsu A; Dos Santos Cirqueira C; Alves VA
World J Gastroenterol; 2016 Jul; 22(27):6246-56. PubMed ID: 27468214
[TBL] [Abstract][Full Text] [Related]
4. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma.
Liu Y; Poon RT; Shao W; Sun X; Chen H; Kok TW; Fan ST
Cancer Lett; 2007 Apr; 248(1):32-40. PubMed ID: 16837130
[TBL] [Abstract][Full Text] [Related]
5. Significance of elevated ERK expression and its positive correlation with EGFR in Kazakh patients with esophageal squamous cell carcinoma.
Cui X; Li S; Li T; Pang X; Zhang S; Jin J; Hu J; Liu C; Yang L; Peng H; Jiang J; Liang W; Suo J; Li F; Chen Y
Int J Clin Exp Pathol; 2014; 7(5):2382-91. PubMed ID: 24966948
[TBL] [Abstract][Full Text] [Related]
6. Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells.
Han C; Michalopoulos GK; Wu T
J Cell Physiol; 2006 Apr; 207(1):261-70. PubMed ID: 16331686
[TBL] [Abstract][Full Text] [Related]
7. Alternative tyrosine phosphorylation of signaling kinases according to hormone receptor status in breast cancer overexpressing the insulin-like growth factor receptor type 1.
Ueda S; Tsuda H; Sato K; Takeuchi H; Shigekawa T; Matsubara O; Hiraide H; Mochizuki H
Cancer Sci; 2006 Jul; 97(7):597-604. PubMed ID: 16827799
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling.
Zimmer S; Kahl P; Buhl TM; Steiner S; Wardelmann E; Merkelbach-Bruse S; Buettner R; Heukamp LC
J Cancer Res Clin Oncol; 2009 May; 135(5):723-30. PubMed ID: 19002495
[TBL] [Abstract][Full Text] [Related]
9. Dual signaling role of the protein tyrosine phosphatase SHP-2 in regulating expression of acute-phase plasma proteins by interleukin-6 cytokine receptors in hepatic cells.
Kim H; Baumann H
Mol Cell Biol; 1999 Aug; 19(8):5326-38. PubMed ID: 10409724
[TBL] [Abstract][Full Text] [Related]
10. The role of EGF-EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment.
Huang P; Xu X; Wang L; Zhu B; Wang X; Xia J
J Cell Mol Med; 2014 Feb; 18(2):218-30. PubMed ID: 24268047
[TBL] [Abstract][Full Text] [Related]
11. ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway.
Wang XJ; Feng CW; Li M
Mol Cell Biochem; 2013 Aug; 380(1-2):57-66. PubMed ID: 23625205
[TBL] [Abstract][Full Text] [Related]
12. LHPP suppresses proliferation, migration, and invasion in hepatocellular carcinoma and pancreatic cancer by inhibiting EGFR signaling pathway.
Zhu H; Song C; Li J; Liu Q; Liu M; Fu L
Med Oncol; 2023 Jul; 40(9):257. PubMed ID: 37522936
[TBL] [Abstract][Full Text] [Related]
13. Effect of phosphorylation of MAPK and Stat3 and expression of c-fos and c-jun proteins on hepatocarcinogenesis and their clinical significance.
Feng DY; Zheng H; Tan Y; Cheng RX
World J Gastroenterol; 2001 Feb; 7(1):33-6. PubMed ID: 11819729
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor (EGF) receptor kinase-independent signaling by EGF.
Deb TB; Su L; Wong L; Bonvini E; Wells A; David M; Johnson GR
J Biol Chem; 2001 May; 276(18):15554-60. PubMed ID: 11279155
[TBL] [Abstract][Full Text] [Related]
15. Novel EGFR-TK inhibitor EKB-569 inhibits hepatocellular carcinoma cell proliferation by AKT and MAPK pathways.
Kim H; Lim HY
J Korean Med Sci; 2011 Dec; 26(12):1563-8. PubMed ID: 22147992
[TBL] [Abstract][Full Text] [Related]
16. IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma.
Gu FM; Li QL; Gao Q; Jiang JH; Zhu K; Huang XY; Pan JF; Yan J; Hu JH; Wang Z; Dai Z; Fan J; Zhou J
Mol Cancer; 2011 Dec; 10():150. PubMed ID: 22171994
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumor cells and normal human keratinocytes.
Nunes M; Shi C; Greenberger LM
Mol Cancer Ther; 2004 Jan; 3(1):21-7. PubMed ID: 14749472
[TBL] [Abstract][Full Text] [Related]
18. Src-dependent phosphorylation of the EGF receptor Tyr-845 mediates Stat-p21waf1 pathway in A431 cells.
Sato K; Nagao T; Iwasaki T; Nishihira Y; Fukami Y
Genes Cells; 2003 Dec; 8(12):995-1003. PubMed ID: 14750954
[TBL] [Abstract][Full Text] [Related]
19. An epidermal growth factor receptor/Jak2 tyrosine kinase domain chimera induces tyrosine phosphorylation of Stat5 and transduces a growth signal in hematopoietic cells.
Nakamura N; Chin H; Miyasaka N; Miura O
J Biol Chem; 1996 Aug; 271(32):19483-8. PubMed ID: 8702638
[TBL] [Abstract][Full Text] [Related]
20. Gastrin-releasing peptide promotes the growth of HepG2 cells via EGFR-independent ERK1/2 activation.
Li X; Lv Y; Yuan A; Yi S; Ma Y; Li Z
Oncol Rep; 2010 Aug; 24(2):441-8. PubMed ID: 20596631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
